A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors

NCT03119428 ↗

Phase 1 Terminated 33 enrolled OncoMed Pharmaceuticals, Inc.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of OMP-31M32 as a single agent or in combination with nivolumab. OMP-313M32 is an experimental anti-TIGIT antibody that was developed to block TIGIT from binding PVR allowing the body's T-cells to destroy cancer cells.

Timeline

Start: 2017-05-02
Primary completion: 2019-05-15
Completion: 2019-05-15

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision”

Publications

Mettu NB, Ulahannan SV, Bendell JC, Garrido-Laguna I, Strickler JH, Moore KN, Stagg R, Kapoun AM, Faoro L, Sharma S. A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. Clin Cancer Res. 2022 Mar 1;28(5):882-892. doi: 10.1158/1078-0432.CCR-21-2780.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Etigilimab	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	Etigilimab	Monoclonal antibody	1 mg/kg	Intravenous
Subject	Etigilimab	Monoclonal antibody	3 mg/kg	Intravenous
Subject	Etigilimab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Etigilimab	Monoclonal antibody	20 mg/kg	Intravenous
Subject	Nivolumab	Monoclonal antibody	240 mg	—